drugset / Trial / NCT00274989

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

NCT00274989 ↗

NaSingle-groupOpen-labelTreatment

Summary

CLL2M is a phase 2, multicenter, open label study to investigate the possible therapeutic benefits of using bendamustine in combination with rituximab for the treatment of patients with previously untreated or relapsed CLL.

Timeline

Start
2005-11
Primary completion
2008-03
Completion
2011-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 70 mg/m2 Intravenous
Subject Bendamustine Small molecule 90 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 500 mg/m2 Intravenous